The case and the decision

A synthetic patient has sensory ataxia, relapsing eye and bulbar weakness, monoclonal IgM and independently confirmed disialosyl IgM. A traumatic CSF specimen contains a few matching clonal cells, while subsequent adequate atraumatic samples are negative. Swallowing, cough and vital capacity are deteriorating.

What MontMedical explains particularly well

Its proportional-admixture calculation predicts about 8.3 circulating clonal cells in the tested CSF aliquot, compared with nine detected events. That makes blood carryover quantitatively sufficient to explain the sparse cells. Matching phenotype, mutation and clonotype may all arrive in the same contaminating blood; they are not automatically three independent demonstrations of CNS residence.

This interpretation is consistent with Bing–Neel guidance warning about blood contamination in CSF cellular and molecular testing. It does not turn negative follow-up samples into a universal exclusion test. [1]

Where OpenEvidence is stronger

OpenEvidence opens with the acute relapse and impending respiratory failure. The retained MontMedical version places the deteriorating cough and vital capacity under additional findings without equally prominent immediate-action wording. On presentation of urgency, OpenEvidence is stronger in this pair.

That matters: an accurate disease name and a careful assay explanation are not enough if the action-relevant finding is easy to miss.

The shared diagnosis and the separate causal question

The clinical pattern is well aligned with the published CANOMAD phenotype. Both tools recognise that an earlier IgG-only anti-GQ1b assay does not answer the later IgM question. [2]

MontMedical also separates the established marrow clone from proof that its reconstructed antibody binds the relevant gangliosides. Testing the clone product would address that narrower causal link. Our preferred design combines that precision with OpenEvidence's clearer prominence of urgency.